Fidia S.p.A. (BIT: FDA)
Italy
· Delayed Price · Currency is EUR | Market Cap | 1.27M |
| Revenue (ttm) | 29.17M |
| Net Income (ttm) | -6.44M |
| Shares Out | 31.09M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,705,120 |
| Open | 0.0438 |
| Previous Close | 0.0438 |
| Day's Range | 0.0400 - 0.0448 |
| 52-Week Range | 0.0398 - 1.1100 |
| Beta | 0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 17, 2025 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. Its accessories comprise HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; K5 tracer, a solution to perform continuous scanning of 3D surfaces; pushbutton panels; XPower digital drives for axis and spindle movement; and... [Read more]
Financial Performance
Financial StatementsNews
Popular Dog Arthritis Medication May Have Severe Side Effects, FDA Says
The drug has been associated with severe side effects such as seizures and muscle control loss, with over 3,600 adverse health reactions reported.
FDA approves Alhemo® injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B with inhibitors
FDA approval is based on data from the pivotal phase 3 trial (explorer7) establishing the safety and efficacy of Alhemo ® for daily prevention of bleeds in adults and pediatric patients 12 years of ag...
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.
Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments
Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments
FDA rejects Lexicon's Zynquista for diabetes, kidney disease
FDA Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea in Adults with Obesity
FDA Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea in Adults with Obesity
FDA approves weight loss drug Zepbound for sleep apnea
Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated w...
Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREKâ¢
Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREKâ¢
Vertex Pharmaceuticals Inc (VRTX) Announces FDA Approval of ALYFTREK for Cystic Fibrosis Treatment
Vertex Pharmaceuticals Inc (VRTX) Announces FDA Approval of ALYFTREK for Cystic Fibrosis Treatment
Rhythm gets FDA approval for Imcivree for toddlers
Pfizer gets FDA accelerated approval for Braftovi
Eggs now qualify as ‘healthy’ food, FDA says: Here’s why
The U.S. Food and Drug Administration (FDA) now classifies eggs as a “healthy, nutrient-dense" food, according to a new proposed rule. Registered dietitians react to the change.
Pfizer Inc (PFE) Gains FDA Approval for New Colorectal Cancer Treatment
Pfizer Inc (PFE) Gains FDA Approval for New Colorectal Cancer Treatment
Rhythm Pharmaceuticals Inc (RYTM) Expands FDA Approval for IMCIVREE® to Treat Young Children ...
Rhythm Pharmaceuticals Inc (RYTM) Expands FDA Approval for IMCIVREE® to Treat Young Children with Rare Obesity Disorders
Catalyst Watch: Labor pains for Amazon & Starbucks, Nasdaq call-up for MicroStrategy and Pony AI ratings
Next week's stock market events include earnings reports, index shuffles, FDA action dates, and the Wall Street Gambit event.
Dow Surges Over 600 Points, Gold Jumps 1.5%
U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 600 points on Friday. The Dow traded up 1.55% to 43,000.53 while the NASDAQ rose 1.65% to 19,693.06. The...
FDA recognises tea as a ‘healthy’ beverage
Kolkata: The Indian Tea Association (ITA) on Friday announced that the US Food and Drug Administration (FDA) has issued a final rule updating the "hea.
Merit Medical gets FDA approval for WRAPSODY dialysis device
Merit Medical Systems (MMSI) has received FDA approval for its WRAPSODY Cell-Impermeable Endoprosthesis device for the treatment of dialysis patients. Read more here.
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday. The Dow traded up 1.82% to 43,111.11 while the NASDAQ rose 1.77% to 19,714.27. The S...
Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining over 300 points on Friday. Shares of Mission Produce, Inc . (NASDAQ: AVO) rose sharply during today's session after the company reported bett...
AVITA gets FDA clearance for Cohealyx for wound care
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?
On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ: HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
Humacyte surges on FDA approval for Symvess vascular repair product
Humacyte (HUMA) stock climbs as FDA approves Symvess, its implantable vascular conduit for arterial injury. Read more here.